Sarah E Monsell1, Lilah M Besser2, Katherine B Heller2, Harvey Checkoway3, Irene Litvan4, Walter A Kukull2. 1. National Alzheimer's Coordinating Center, University of Washington, Seattle, WA 98105, USA. Electronic address: smonsell@uw.edu. 2. National Alzheimer's Coordinating Center, University of Washington, Seattle, WA 98105, USA. 3. Department of Family & Preventive Medicine, University of California, San Diego, La Jolla, CA, USA. 4. Department of Neurosciences, University of California, San Diego, La Jolla, CA, USA.
Abstract
BACKGROUND: Apolipoprotein (APOE) e4 allele status has been linked to clinical presentation and progression in Alzheimer's disease; however, evidence for a role of APOE e4 in Parkinson's disease (PD) remains largely inconclusive. In this analysis we explored potential significant associations between APOE e4 allele status and characteristics of clinical presentation in patients with PD. METHODS: Data came from 424 subjects evaluated using the Uniform Data Set (UDS) assessment collected by the National Alzheimer's Coordinating Center. Subjects had a known year of diagnosis of PD and experienced change in motor function prior to any change in cognition. Linear and logistic regression were used to model the association between APOE e4 carrier status and clinical characteristics including measures of cognitive decline and motor and neuropsychiatric symptoms. Amyloid burden was also evaluated for a subset of patients who died and consented to autopsy. RESULTS: Odds of dementia were higher in APOE e4 carriers (OR = 5.15), and, on average, APOE e4 carriers scored two points worse on tests of episodic memory and the Clinical Dementia Rating Sum of Boxes assessment. There was little evidence to support an association between e4 carrier status and severity of motor features, and, of the four neuropsychiatric symptoms evaluated, only presence of hallucinations was significantly associated with APOE e4 carrier status (OR = 5.29). Neuropathology data revealed higher frequencies of neuritic and diffuse amyloid plaques in APOE e4 carriers compared to non-carriers. CONCLUSIONS: APOE e4 allele status is associated with dementia and severity of Alzheimer's disease pathologic features in PD.
BACKGROUND:Apolipoprotein (APOE) e4 allele status has been linked to clinical presentation and progression in Alzheimer's disease; however, evidence for a role of APOE e4 in Parkinson's disease (PD) remains largely inconclusive. In this analysis we explored potential significant associations between APOE e4 allele status and characteristics of clinical presentation in patients with PD. METHODS: Data came from 424 subjects evaluated using the Uniform Data Set (UDS) assessment collected by the National Alzheimer's Coordinating Center. Subjects had a known year of diagnosis of PD and experienced change in motor function prior to any change in cognition. Linear and logistic regression were used to model the association between APOE e4 carrier status and clinical characteristics including measures of cognitive decline and motor and neuropsychiatric symptoms. Amyloid burden was also evaluated for a subset of patients who died and consented to autopsy. RESULTS: Odds of dementia were higher in APOE e4 carriers (OR = 5.15), and, on average, APOE e4 carriers scored two points worse on tests of episodic memory and the Clinical Dementia Rating Sum of Boxes assessment. There was little evidence to support an association between e4 carrier status and severity of motor features, and, of the four neuropsychiatric symptoms evaluated, only presence of hallucinations was significantly associated with APOE e4 carrier status (OR = 5.29). Neuropathology data revealed higher frequencies of neuritic and diffuse amyloid plaques in APOE e4 carriers compared to non-carriers. CONCLUSIONS:APOE e4 allele status is associated with dementia and severity of Alzheimer's disease pathologic features in PD.
Authors: Meghan C Campbell; Joanne Markham; Hubert Flores; Johanna M Hartlein; Alison M Goate; Nigel J Cairns; Tom O Videen; Joel S Perlmutter Journal: Neurology Date: 2013-07-03 Impact factor: 9.910
Authors: D I Kaufer; J L Cummings; P Ketchel; V Smith; A MacMillan; T Shelley; O L Lopez; S T DeKosky Journal: J Neuropsychiatry Clin Neurosci Date: 2000 Impact factor: 2.198
Authors: David J Irwin; Matthew T White; Jon B Toledo; Sharon X Xie; John L Robinson; Vivianna Van Deerlin; Virginia M-Y Lee; James B Leverenz; Thomas J Montine; John E Duda; Howard I Hurtig; John Q Trojanowski Journal: Ann Neurol Date: 2012-10-04 Impact factor: 10.422
Authors: Stephen N Gomperts; Joseph J Locascio; Dorene Rentz; Andrea Santarlasci; Marta Marquie; Keith A Johnson; John H Growdon Journal: Neurology Date: 2012-12-12 Impact factor: 9.910
Authors: Debby Tsuang; James B Leverenz; Oscar L Lopez; Ronald L Hamilton; David A Bennett; Julie A Schneider; Aron S Buchman; Eric B Larson; Paul K Crane; Jeffrey A Kaye; Patricia Kramer; Randy Woltjer; John Q Trojanowski; Daniel Weintraub; Alice S Chen-Plotkin; David J Irwin; Jacqueline Rick; Gerard D Schellenberg; G Stennis Watson; Walter Kukull; Peter T Nelson; Gregory A Jicha; Janna H Neltner; Doug Galasko; Eliezer Masliah; Joseph F Quinn; Kathryn A Chung; Dora Yearout; Ignacio F Mata; Jia Y Wan; Karen L Edwards; Thomas J Montine; Cyrus P Zabetian Journal: JAMA Neurol Date: 2013-02 Impact factor: 18.302
Authors: Rizwan S Akhtar; Sharon X Xie; Yin J Chen; Jacqueline Rick; Rachel G Gross; Ilya M Nasrallah; Vivianna M Van Deerlin; John Q Trojanowski; Alice S Chen-Plotkin; Howard I Hurtig; Andrew D Siderowf; Jacob G Dubroff; Daniel Weintraub Journal: PLoS One Date: 2017-05-25 Impact factor: 3.240